SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more
SkinBioTherapeutics PLC (SBTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.053x
Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has a cash flow conversion efficiency ratio of -0.053x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-494.84K) by net assets (GBX9.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SkinBioTherapeutics PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
SkinBioTherapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SkinBioTherapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ellcot Spinning Mills Ltd
KAR:ELSM
|
N/A |
|
5 Year Fixed Rate
KAR:P05FRR100529
|
N/A |
|
PT Astra Agro Lestari Tbk
MU:ASX
|
N/A |
|
Vinacomin Mong Duong Coal JSC
VN:MDC
|
N/A |
|
Towellers Ltd
KAR:TOWL
|
N/A |
|
Gol Intelligent Airlines Inc
STU:GOQN
|
0.024x |
|
K3 Business Technology Group PLC
LSE:KBT
|
0.278x |
|
67GX
LSE:67GX
|
N/A |
Annual Cash Flow Conversion Efficiency for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of SkinBioTherapeutics PLC from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX9.42 Million | GBX-1.30 Million | -0.138x | +84.99% |
| 2024-06-30 | GBX2.97 Million | GBX-2.73 Million | -0.918x | +30.77% |
| 2023-06-30 | GBX1.99 Million | GBX-2.65 Million | -1.326x | -22.79% |
| 2022-06-30 | GBX2.48 Million | GBX-2.67 Million | -1.080x | -262.16% |
| 2021-06-30 | GBX5.22 Million | GBX-1.56 Million | -0.298x | +17.59% |
| 2020-06-30 | GBX2.47 Million | GBX-892.14K | -0.362x | +3.51% |
| 2019-06-30 | GBX3.81 Million | GBX-1.43 Million | -0.375x | -93.22% |
| 2018-06-30 | GBX3.44 Million | GBX-667.75K | -0.194x | -34.11% |
| 2017-06-30 | GBX4.21 Million | GBX-609.70K | -0.145x | -4733.88% |
| 2016-06-30 | GBX389.85K | GBX-1.17K | -0.003x | -- |